Tag Archives: NSCLC

#WCLC2018 conclusions – Strategies to Maximize the Clinical Benefit of EGFR TKIs in Advanced NSCLC

During the congress, one of the topics covered focused on the importance of EGFR TKIs in Advanced NSCLC. Apply expert recommendations for frontline therapy for advanced EGFR-mutated NSCLC focusing on safety, efficacy, and the individualization of therapy based on tumor-specific and patient-specific factors Compare the efficacy and safety of first-generation EGFR TKIs with later-generation EGFR TKIs Examine current recommendations for molecular […]

Read More

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of NSCLC

Due to the distinct features of cancer immunotherapy, and rapid progress in the field, clinical guidance is needed on the use of these agents, including appropriate patient selection, sequencing of therapies, response monitoring, adverse event management, and biomarker testing. The Society for Immunotherapy of Cancer (SITC) convened an expert Task Force charged with developing consensus recommendations on these key issues. […]

Read More